Barrett's oesophagus: Evidence from the current meta-analyses
- PMID: 25133020
- PMCID: PMC4133517
- DOI: 10.4291/wjgp.v5.i3.178
Barrett's oesophagus: Evidence from the current meta-analyses
Abstract
Guidelines have been published regarding the management of Barrett's oesophagus (columnar-lined oesophagus). These have examined the role of surveillance in an effort to detect dysplasia and early cancer. The guidelines have provided criteria for enrolment into surveillance and some risk stratification with regard to surveillance interval. The research basis for the decisions reached with regard to cancer risk is weak and this manuscript has examined the available data published from meta-analyses up to 25(th) April 2013 (much of which has been published since the guidelines and their most recent updates have been written). There were 9 meta-analyses comparing patients with Barrett's oesophagus to control populations. These have demonstrated that Barrett's oesophagus is more common in males than females, in subjects who have ever smoked, in subjects with obesity, in subjects with prolonged symptoms of gastro-oesophageal reflux disease, in subjects who do not have infection with Helicobacter pylori and in subjects with hiatus hernia. These findings should inform public health measures in reducing the risk of Barrett's oesophagus and subsequent surveillance burden and cancer risk. There were 8 meta-analyses comparing different groups of patients with Barrett's oesophagus with regard to cancer risk. These have demonstrated that there was no statistically significant benefit of antireflux surgery over medical therapy, that endoscopic ablative therapy was effective in reducing cancer risk that there was similar cancer risk in patients with Barrett's oesophagus independent of geographic origin, that the adenocarcinoma incidence in males is twice the rate in females, that the cancer risk in long segment disease showed a trend to be higher than in short segment disease, that there was a trend for higher cancer risk in low-grade dysplasia over non-dysplastic Barrett's oesophagus, that there is a lower risk in patients with Helicobacter pylori infection and that there is a significant protective effect of aspirin and statins. There were no meta-analyses examining the role of intestinal metaplasia. These results demonstrate that guidance regarding surveillance based on the presence of intestinal metaplasia, segment length and the presence of low-grade dysplasia has a weak basis, and further consideration should be given to gender and helicobacter status, ablation of the metaplastic segment as well as the chemoprotective role of aspirin and statins.
Keywords: Barrett esophagus; Esophageal neoplasms; Meta-analysis; Review; Systematic.
Similar articles
-
Barrett's oesophagus: epidemiology, diagnosis and clinical management.Med J Aust. 2016 Oct 3;205(7):317-24. doi: 10.5694/mja16.00796. Med J Aust. 2016. PMID: 27681974 Review.
-
Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.Aust N Z J Surg. 2000 Jan;70(1):26-33. doi: 10.1046/j.1440-1622.2000.01737.x. Aust N Z J Surg. 2000. PMID: 10696939 Review.
-
Diagnosis and treatment of Barrett's oesophagus. A general survey.Acta Chir Belg. 2001 Mar-Apr;101(2):53-8. Acta Chir Belg. 2001. PMID: 11396051 Review.
-
Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.Histopathology. 2005 Sep;47(3):268-75. doi: 10.1111/j.1365-2559.2005.02219.x. Histopathology. 2005. PMID: 16115227
-
Recent advances in oesophageal diseases.Gastroenterol Hepatol Bed Bench. 2014 Summer;7(3):186-9. Gastroenterol Hepatol Bed Bench. 2014. PMID: 25120902 Free PMC article.
Cited by
-
The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.Am J Gastroenterol. 2015 Jun;110(6):828-34. doi: 10.1038/ajg.2015.152. Epub 2015 May 26. Am J Gastroenterol. 2015. PMID: 26010308 Free PMC article.
-
Surveillance in Barrett esophagus.J Med Life. 2014;7 Spec No. 3(Spec Iss 3):61-7. J Med Life. 2014. PMID: 25870698 Free PMC article.
-
Esophageal Adenocarcinoma in the Proximal Esophageal Segment: A Unique Presentation in a Male With Alcohol Abuse.Cureus. 2020 Jun 27;12(6):e8863. doi: 10.7759/cureus.8863. Cureus. 2020. PMID: 32754402 Free PMC article.
-
Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?Transl Gastroenterol Hepatol. 2018 Dec 5;3:101. doi: 10.21037/tgh.2018.11.07. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 30701208 Free PMC article. Review.
-
Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.World J Gastroenterol. 2016 Dec 28;22(48):10592-10600. doi: 10.3748/wjg.v22.i48.10592. World J Gastroenterol. 2016. PMID: 28082811 Free PMC article.
References
-
- Gatenby PA, Caygill CP, Ramus JR, Charlett A, Watson A. Barrett’s columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci. 2008;53:1175–1185. - PubMed
-
- Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42. - PubMed
-
- Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797. - PubMed
-
- Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091. - PubMed
-
- Andrici J, Tio M, Cox MR, Eslick GD. Meta-analysis: Barrett’s oesophagus and the risk of colonic tumours. Aliment Pharmacol Ther. 2013;37:401–410. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous